Cohance Lifesciences Q4 & FY26 Earnings Call Transcript Released
Cohance Lifesciences released its Q4 & FY26 earnings call transcript. The Pharma CDMO business reported FY26 revenue of ₹8.89 billion (approx. ₹889 crore), API Plus ₹10.88 billion (approx. ₹1088 crore), and Specialty Chemicals ₹2.913 billion (approx. ₹291.3 crore). Consolidated revenue declined 13% to ₹22.68 billion (approx. ₹2268 crore). Q1 FY27 is expected to be weak, with recovery anticipated from H2 FY27.
The announcement provides a comprehensive update on the company's financial performance for FY26 and its outlook for FY27, including segment-wise details and management's strategic priorities. This information is material for investors to assess the company's current standing and future prospects.
The transcript details the company's financial performance and strategic outlook. While it addresses challenges like revenue decline and destocking, it also outlines future growth plans and management's commitment to improving performance, leading to a neutral sentiment.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) has released the transcript of its earnings conference call held on May 12, 2026, for the quarter and year ended March 31, 2026. The call featured Executive Chairman and Group CEO, Mr. Umang Vohra, in his first earnings call with the company, alongside other key management personnel including Mr. Yann (CEO Pharma CDMO), Mr. Gunjan (CEO API +), Mr. Amrit (Head Specialty Chemical), and Mr. Himanshu Agarwal (Whole-Time Director and CFO).
Mr. Vohora expressed excitement about Cohance's scientific capabilities in ADCs and oligonucleotides, highlighting his immediate priority to develop a strategic blueprint for growth and sustainable value creation by the end of the fiscal year. He emphasized focusing on predictability of delivery, quality, systems, talent, and a relevant pipeline.
The Pharma CDMO business reported FY26 revenue of ₹8.89 billion (approximately ₹889 crore), with underlying growth in the early single digits after adjusting for destocking. The business has over 140 active projects, with two programs progressing towards commercialization and a total Phase 3 pipeline of 10 programs. Capex of $10 million is underway at the NJ Bio US facility to support future scale-up.
The API Plus business reported FY26 revenues of ₹10.88 billion (approximately ₹1088 crore), a decline of 8% year-on-year, attributed to product-specific factors, shipment delays, and temporary disruption at the Nacharam formulation site. The company completed 10 new filings and validated six new products during FY26. Production and US supplies at the Nacharam site have resumed.
The Specialty Chemicals business reported FY26 revenue of ₹2.913 billion (approximately ₹291.3 crore), a marginal decline of 2.1% year-on-year, impacted by customer program phasing and regulatory timing. For FY27, the focus is on converting customer qualifications and RFQs into revenue, with growth expected in FY28.
Financially, for FY26, consolidated revenue stood at ₹22.68 billion (approximately ₹2268 crore), a decline of approximately 13% year-on-year. Adjusted EBITDA was ₹4.77 billion (approximately ₹477 crore), with an EBITDA margin of 21%. Standalone adjusted EBITDA margin was 24.6%. Capex for the year was ₹2.15 billion (approximately ₹215 crore), with an expected ₹3 billion (approximately ₹300 crore) in FY27. Free cash generated in FY26 was ₹1.73 billion (approximately ₹173 crore). The company anticipates Q1 FY27 to be low in both revenue and EBITDA, with recovery expected from the second half of FY27, driven by improving volumes, order conversion, and product mix normalization. Uncertainties in the Middle East region are expected to impact Q1 FY27 gross margins by 100-150 bps, largely on account of the API Plus business.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.